BioinvestGPT User Guide — Clinically Derisk Indications (EXPANSION)

Predict head-to-head effect sizes versus standard of care before investing in a label expansion.

When to use the EXPANSION mission

Run the Indications mission when you already have an approved drug and you want to know whether it is worth pursuing a label expansion into a new indication. Instead of asking "does this molecule work at all?", you are asking a sharper commercial question: "in the new indication, how does my drug perform head-to-head against the standard of care that is already there?"

What makes EXPANSION different: The platform stratifies the population of the target indication — not the original one — and predicts head-to-head effect sizes versus the current standard of care in that new setting. You are derisking a market you have not entered yet, using a drug whose safety and PK are already characterised.

Where this mission fits

You have...	You want to know...	Use
An approved drug on the market	Whether to expand its label into a new indication	Indications (EXPANSION)
A novel target with no trial history	Whether the target-disease hypothesis holds	FIC Targets (HYPOTHESIS)

Because the drug is already approved, the EXPANSION analysis focuses on transferability of effect: will the mechanism that earned approval in the current indication produce a competitive effect size in the target indication, against the drugs patients already receive there?

Tip: Reach for EXPANSION before you commission a Phase 2 basket or a competitor-controlled study. The point is to predict the head-to-head outcome cheaply, so you only fund the expansion trials with a favourable predicted effect size.

Enter the expansion opportunity

From the Hub, click "Start" on the Indications card. The Validator opens on the EXPANSION mission. Fill in the four fields that define the opportunity:

Field	What to enter
Approved Drug	Your drug that is already on the market.
Current Indication	Where the drug is approved today.
Target Indication	The new indication you want to expand into.
Competitive Drugs	The drugs you would be up against in the new indication — the standard of care patients receive there.

The platform stratifies the new indication's population (not the original) and predicts head-to-head effect sizes versus the current standard of care.

Tip: List the competitive drugs the way a payer or KOL would describe the standard of care in the target indication, not just the single closest analogue — the head-to-head prediction is only as good as the comparator set you give it.

Why these four fields drive the prediction

Each field plays a distinct role in the simulation:

Approved Drug anchors the mechanism, dose range, and safety profile that already exist — this is what makes the expansion cheaper than a first-in-class program.
Current Indication establishes the baseline of what the drug is known to do, so the platform can reason about how that effect transfers.
Target Indication selects the disease biology and patient population the strata will be synthesized from.
Competitive Drugs define the bar: the predicted effect is reported relative to these comparators, which is what turns the output into a go/no-go on the expansion.

Stratify the right population: EXPANSION deliberately stratifies the target indication, not the current one. If you find the strata describing your original patients, you have likely swapped the Current and Target fields — return to the form and correct them before reading the results.

Head-to-head vs standard of care

After you submit the opportunity, the platform synthesizes virtual patient subgroups for the target indication and predicts, for each stratum, how your approved drug performs head-to-head against the competitive drugs you listed — the current standard of care in that new setting. This is the core deliverable of the EXPANSION mission.

Reading the head-to-head output

Each stratum's predicted effect size is expressed relative to the standard of care, so the comparison is direct rather than a single-arm estimate:

Metric	Example	How to read it head-to-head
Hazard Ratio (HR)	HR = 0.72	28% lower risk of the event versus the standard-of-care comparator. Lower is better.
Odds Ratio (OR)	OR = 1.8	1.8x higher odds of response versus standard of care. Higher is better.
95% Confidence Interval	HR 0.72 (0.55-0.94)	If the interval crosses 1.0, the head-to-head advantage is not statistically distinguishable.

Turning the prediction into a GO/NO-GO

The same verdict logic used elsewhere in the platform applies to the head-to-head result:

Badge	Meaning for the expansion
GO	The drug beats standard of care by your target margin in at least one enrollable stratum — the expansion is worth a confirmatory trial.
CONDITIONAL GO	The advantage is borderline or confined to specific subgroups — review the per-stratum head-to-head data before committing.
NO-GO	The drug does not separate from the existing standard of care — the expansion is unlikely to clear a competitive bar.

Tip: A CONDITIONAL GO concentrated in a coherent, enrollable subgroup is often the most actionable result — it points toward a biomarker-enriched expansion trial against standard of care rather than an all-comers study you would lose on price.

What a favourable head-to-head buys you

A predicted advantage over the incumbent standard of care, concentrated in a stratum you can actually enroll, is the evidence that justifies funding the expansion program. Where the head-to-head shows no separation, you have spared the cost of a comparator-controlled trial that was unlikely to win.

Decision support, not a guarantee: A BVCT head-to-head verdict is a model-based decision-support analysis, not investment advice and not a regulatory endorsement. Use it to prioritise which expansions to fund and how to design them — pair it with confirmatory clinical evidence before committing resources.

You can audit how BVCT predictions have held up against real outcomes on the prospective track record at data.bioinvestgpt.com.

Where to go next

To open the Validator directly for another expansion opportunity, go to bvct.bioinvestgpt.com/#/validator. To revisit any past expansion, open the Expansion panel in the left sidebar pipeline history and click a record to view its head-to-head results.

BioinvestGPT BVCT Platform User Guide — Clinically Derisk Indications (EXPANSION). BVCT outputs are model-based decision-support analyses, not investment advice. Prospective track record: data.bioinvestgpt.com.